Progyny (NASDAQ:PGNY) EVP Allison Swartz Sells 2,199 Shares

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 2,199 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $17.27, for a total transaction of $37,976.73. Following the transaction, the executive vice president owned 97,378 shares in the company, valued at approximately $1,681,718.06. The trade was a 2.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Allison Swartz also recently made the following trade(s):

• On Tuesday, March 3rd, Allison Swartz sold 4,657 shares of Progyny stock. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80.
• On Thursday, December 4th, Allison Swartz sold 530 shares of Progyny stock. The stock was sold at an average price of $24.59, for a total transaction of $13,032.70.

Progyny Stock Up 1.5%

PGNY stock traded up $0.27 during trading on Wednesday, hitting $17.79. 2,389,172 shares of the company’s stock traded hands, compared to its average volume of 1,591,542. The firm has a market capitalization of $1.46 billion, a P/E ratio of 27.37, a PEG ratio of 1.20 and a beta of 1.01. Progyny, Inc. has a 1 year low of $16.75 and a 1 year high of $28.75. The business has a fifty day simple moving average of $23.56 and a two-hundred day simple moving average of $23.04.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.10. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The business had revenue of $318.40 million for the quarter, compared to analysts’ expectations of $314.26 million. During the same quarter last year, the firm earned $0.42 EPS. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, equities research analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Progyny

Institutional investors and hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP grew its holdings in shares of Progyny by 260.9% during the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after buying an additional 1,621,688 shares during the last quarter. Loomis Sayles & Co. L P acquired a new stake in Progyny during the 4th quarter worth about $19,917,000. Barclays PLC grew its stake in Progyny by 79.2% during the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after purchasing an additional 696,447 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after purchasing an additional 545,431 shares during the period. Finally, Jupiter Asset Management Ltd. acquired a new position in shares of Progyny in the second quarter valued at about $10,525,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PGNY has been the subject of a number of recent research reports. Citizens Jmp upgraded shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 target price for the company in a report on Tuesday, January 20th. Canaccord Genuity Group increased their target price on shares of Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a research report on Monday, November 17th. Truist Financial lowered their target price on shares of Progyny from $34.00 to $28.00 and set a “buy” rating for the company in a research note on Monday. Barclays initiated coverage on Progyny in a research report on Monday, December 8th. They set an “overweight” rating and a $29.00 price target on the stock. Finally, BTIG Research reissued a “buy” rating on shares of Progyny in a research report on Wednesday, January 21st. Eight equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Progyny currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.80.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.